Compound Reviews
TB-500 and Thymosin Beta-4: What the Research Describes
TB-500 is a fragment, not the full protein. The distinction matters for how the published thymosin beta-4 literature should be read.
Published August 6, 2026 · 6 min read
By Novanta Research
Fragment versus full sequence
Thymosin beta-4 is a naturally occurring 43-residue protein whose principal described function is binding G-actin and regulating actin polymerisation inside cells. TB-500 as sold in the research market is a shorter synthetic fragment containing the actin-binding region.
Much of the literature cited around TB-500 actually studies full-length thymosin beta-4. The two are related but not identical, and conclusions do not transfer automatically from one to the other.
Described mechanisms
Actin sequestration is the best-characterised activity: by binding monomeric actin, the protein influences cytoskeletal remodelling, which in turn affects cell migration. Migration is central to how tissue reorganises after injury, which is the thread running through most of the animal work.
Additional papers describe angiogenic and anti-inflammatory effects in specific models, though mechanistic detail there is thinner.
How to read the evidence
As with BPC-157, the body of work is preclinical. Where human data exist, they mostly come from small early-phase studies of full-length thymosin beta-4 in specific indications rather than of the research fragment.
For laboratory purposes the practical takeaway is to specify precisely which molecule a protocol uses, and to verify identity by mass rather than relying on a market name.
Compound references
Continue with the cited research overview
Keep reading
For laboratory and research use only. Not for human or veterinary consumption. Novanta Research is not a compounding pharmacy and nothing in this article is medical advice or a claim that any compound diagnoses, treats, cures or prevents any condition.